Uroplasty (NASDAQ:UPI) Receiving Somewhat Favorable News Coverage, Report Shows

Media coverage about Uroplasty (NASDAQ:UPI) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Uroplasty earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news articles about the medical device company an impact score of 44.410131304601 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Uroplasty opened at $1.22 on Friday, MarketBeat Ratings reports. Uroplasty has a 52-week low of $1.05 and a 52-week high of $4.05.

Uroplasty Company Profile

Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.

Insider Buying and Selling by Quarter for Uroplasty (NASDAQ:UPI)

Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply